GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS in collaboration with NINDS, Secures Rights

GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS in collaboration with NINDS, Secures Rights

  • Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide development rights
  • GeNeuro launches pHERV-K Env antibody development program, aiming to reach IND by mid-2020

Geneva, Switzerland, October 17, 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that following a successful collaboration in preclinical amyotrophic lateral sclerosis (ALS) models, the Company has signed an exclusive worldwide license with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH).

More information on : https://www.newcontact.eu/secure/media/com_newcap/files/files/GeNeuro%20PR%20NIH%20ALS%20License%20Press%20release_ENG.pdf